Oppenheimer & Co’s AbbVie ABBV Stock Holding History

Oppenheimer & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33.9M	Sell	156,065 -3,382	-2%	-$750K	0.41%	41
2025 Q4	$36.4M	Sell	159,447 -8,094	-5%	-$1.84M	0.52%	29
2025 Q3	$38.8M	Buy	167,541 +5,688	+4%	+$1.16M	0.47%	30
2025 Q2	$30M	Buy	161,853 +9,246	+6%	+$1.72M	0.4%	34
2025 Q1	$32M	Buy	152,607 +2,738	+2%	+$532K	0.48%	30
2024 Q4	$26.6M	Buy	149,869 +1,103	+0.7%	+$203K	0.4%	36
2024 Q3	$29.4M	Sell	148,766 -4,856	-3%	-$906K	0.45%	33
2024 Q2	$26.3M	Buy	153,622 +3,259	+2%	+$540K	0.42%	36
2024 Q1	$27.4M	Sell	150,363 -4,889	-3%	-$843K	0.45%	34
2023 Q4	$24.1M	Buy	155,252 +2,727	+2%	+$398K	0.44%	34
2023 Q3	$22.7M	Sell	152,525 -2,492	-2%	-$366K	0.47%	31
2023 Q2	$20.9M	Sell	155,017 -14,163	-8%	-$2.08M	0.42%	38
2023 Q1	$27M	Buy	169,180 +9,732	+6%	+$1.49M	0.57%	22
2022 Q4	$25.8M	Sell	159,448 -1,663	-1%	-$255K	0.59%	22
2022 Q3	$21.6M	Sell	161,111 -5,785	-3%	-$830K	0.51%	26
2022 Q2	$25.6M	Sell	166,896 -8,876	-5%	-$1.36M	0.55%	25
2022 Q1	$28.5M	Sell	175,772 -10,200	-5%	-$1.48M	0.51%	25
2021 Q4	$25.2M	Sell	185,972 -4,224	-2%	-$499K	0.44%	37
2021 Q3	$20.5M	Buy	190,196 +6,956	+4%	+$795K	0.38%	45
2021 Q2	$20.6M	Buy	183,240 +166	+0.1%	+$18.7K	0.37%	50
2021 Q1	$19.8M	Buy	183,074 +7,620	+4%	+$815K	0.4%	45
2020 Q4	$18.8M	Sell	175,454 -3,460	-2%	-$332K	0.4%	51
2020 Q3	$15.7M	Sell	178,914 -90,130	-34%	-$8.49M	0.39%	48
2020 Q2	$26.4M	Buy	269,044 +55,313	+26%	+$4.87M	0.68%	22
2020 Q1	$16.3M	Buy	213,731 +19,360	+10%	+$1.65M	0.49%	37
2019 Q4	$17.2M	Buy	194,371 +27,860	+17%	+$2.31M	0.43%	52
2019 Q3	$12.6M	Buy	166,511 +6,302	+4%	+$432K	0.34%	60
2019 Q2	$11.7M	Buy	160,209 +32,122	+25%	+$2.52M	0.32%	65
2019 Q1	$10.3M	Sell	128,087 -61,994	-33%	-$5.07M	0.28%	80
2018 Q4	$17.5M	Sell	190,081 -3,781	-2%	-$333K	0.55%	37
2018 Q3	$18.3M	Sell	193,862 -9,795	-5%	-$929K	0.47%	44
2018 Q2	$18.9M	Buy	203,657 +3,114	+2%	+$304K	0.51%	41
2018 Q1	$19M	Sell	200,543 -23,504	-10%	-$2.58M	0.49%	44
2017 Q4	$21.7M	Sell	224,047 -8,918	-4%	-$840K	0.56%	31
2017 Q3	$20.7M	Buy	232,965 +3,626	+2%	+$276K	0.55%	34
2017 Q2	$16.6M	Buy	229,339 +5,702	+3%	+$383K	0.46%	40
2017 Q1	$14.6M	Buy	223,637 +21,548	+11%	+$1.35M	0.41%	50
2016 Q4	$12.7M	Sell	202,089 -23,525	-10%	-$1.44M	0.37%	63
2016 Q3	$14.2M	Buy	225,614 +4,853	+2%	+$314K	0.41%	58
2016 Q2	$13.7M	Sell	220,761 -14,865	-6%	-$906K	0.41%	56
2016 Q1	$13.5M	Buy	235,626 +29,199	+14%	+$1.63M	0.41%	57
2015 Q4	$12.2M	Buy	206,427 +27,025	+15%	+$1.56M	0.36%	63
2015 Q3	$9.76M	Buy	179,402 +8,880	+5%	+$578K	0.3%	77
2015 Q2	$11.5M	Buy	170,522 +9,038	+6%	+$590K	0.32%	61
2015 Q1	$9.45M	Sell	161,484 -2,796	-2%	-$169K	0.26%	91
2014 Q4	$10.8M	Sell	164,280 -3,623	-2%	-$228K	0.31%	71
2014 Q3	$9.7M	Buy	167,903 +10,340	+7%	+$574K	0.29%	80
2014 Q2	$8.89M	Sell	157,563 -11,288	-7%	-$592K	0.27%	83
2014 Q1	$8.68M	Sell	168,851 -12,910	-7%	-$652K	0.26%	85
2013 Q4	$9.6M	Sell	181,761 -15,311	-8%	-$753K	0.31%	68
2013 Q3	$8.81M	Sell	197,072 -19,777	-9%	-$877K	0.31%	70
2013 Q2	$8.96M	Buy	+216,849	New	+$9.48M	0.35%	62

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Oppenheimer & Co's ABBV Position: Q1 2026 in Review

Oppenheimer & Co reduced its AbbVie (ABBV) stake by 2.1% in Q1 2026, selling an estimated $750K and leaving 156,065 shares worth $33.9M. The position accounts for 0.41% of the portfolio, ranked #41.

Oppenheimer & Co first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $38.8M in Q3 2025. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Oppenheimer & Co held 156,065 shares of AbbVie worth $33.9M as of Q1 2026.
Oppenheimer & Co sold 3,382 AbbVie shares in Q1 2026, an estimated $750K.
AbbVie made up 0.41% of Oppenheimer & Co's portfolio in Q1 2026, its #41 holding.
Oppenheimer & Co first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Oppenheimer & Co's AbbVie position peaked at $38.8M in Q3 2025.
4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.